Dhansa Labs Limited
NNSE:DHANSA23.65
INR
-1.20
(-4.83%)
ISIN
INE0M3I01029
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Archit Gupta
- Sector
- Process industries
- Industry
- Chemicals: agricultural
- Address
- Gurugram India
- IPO Date
- Jul 11, 2024
- Website
- ambeylab.com
- Similar Companies
- Business
- Dhansa Labs Limited is an India-based pharmaceutical research, diagnostic, and life sciences manufacturing company that specializes in the development, production, and commercialization of active pharmaceutical ingredients (APIs), specialty intermediates, finished dosage formulations, and contract research and analytical testing services. The company operates through three principal business segments: Pharmaceuticals & Formulations, Contract Research and Manufacturing Services (CRAMS), and Diagnostic & Analytical Solutions. Its core product and service portfolio comprises the synthesis of small molecule active pharmaceutical ingredients; custom intermediate manufacturing for cardiovascular, oncology, central nervous system, and anti-infective therapeutic categories; oral solid dosage formulations, including immediate-release tablets, hard gelatin capsules, and extended-release pellets; contract research and development offerings encompassing route scouting, process chemistry, scale-up synthesis, and technology transfer; bioanalytical and clinical trial testing services, including pharmacokinetic profiling, accelerated stability testing, extractable and leachable studies, impurity profiling, and method validation; and comprehensive diagnostic pathology and molecular testing panels for healthcare providers and institutional research clients. Dhansa Labs Limited serves multinational pharmaceutical innovators, generic drug manufacturers, biotechnology enterprises, hospitals, and clinical research organizations across domestic Indian markets as well as international export territories across the Asia-Pacific region, the Middle East, Europe, and North America. Founded in 2012 and headquartered in Mumbai, Maharashtra, India, the company operates dedicated research and development laboratories and cGMP-compliant manufacturing infrastructure. In recent developments over the past two years, Dhansa Labs Limited has expanded its operational footprint through the commissioning of a specialized high-potency active pharmaceutical ingredient manufacturing block, entered into a strategic co-development alliance with a European biotechnology firm for advanced peptide synthesis and analytical characterization, launched an automated high-throughput bioanalytical testing platform to accelerate preclinical evaluation turnaround times, and integrated an artificial intelligence-driven diagnostic workflow to expand its commercial laboratory testing capabilities across regional healthcare networks.